title: Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants.
abstract: The aim of this study was to formulate cost effective taste-masked orally disintegrating tablets of ondansetron, a bitter drug using different superdisintegrants by a wet granulation technique. Microcrystalline cellulose (Avicel) as a diluent and disintegrant in addition to aspartame as a sweetener were used in all formulations. The prepared tablets were evaluated for weight variation, thickness, hardness, friability, drug content, water content, in vitro disintegration time and in vitro drug release. The tablets' hardness was maintained in the range of 2-3 kg and friability was <1% for all batches. All tablet formulations disintegrated rapidly in vitro within 5.83 to 33.0 sec. The optimized formulation containing 15% Polyplasdone XL-10 released more than 90% of drug within 5 min and the release was comparable to that of a commercial product. In human volunteers, optimized formulation was found to have a pleasant taste and mouth feel and they disintegrated in the oral cavity within 12 sec. The stability results were also satisfactory. A pharmacokinetic study with the optimized formulation was performed in comparison with a reference (Zofer MD 8®) and they were found to be bioequivalent. In conclusion, a cost effective ondansetron orally disintegrating tablet was successfully prepared with acceptable hardness, desirable taste and rapid disintegration in the oral cavity.
authors.affiliation: School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.
authors.forename: Ravi
authors.initials: R
authors.lastname: Sheshala
authors.forename: Nurzalina
authors.initials: N
authors.lastname: Khan
authors.forename: Mallikarjun
authors.initials: M
authors.lastname: Chitneni
authors.forename: Yusrida
authors.initials: Y
authors.lastname: Darwis
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000818:Animals; D000932:Antiemetics / Q000032:analysis / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000494:pharmacology; D001682:Biological Availability; D055598:Chemical Phenomena; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D008297:Male; D017294:Ondansetron / Q000032:analysis / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000494:pharmacology; D011817:Rabbits; D011897:Random Allocation; D012677:Sensation; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000032:analysis / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000494:pharmacology; D012995:Solubility; D013549:Sweetening Agents / Q000737:chemistry / Q000494:pharmacology; D013607:Tablets; D013649:Taste
chemical_list: D000932:Antiemetics; D005079:Excipients; D058831:Serotonin 5-HT3 Receptor Antagonists; D013549:Sweetening Agents; D013607:Tablets; D017294:Ondansetron